These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 1941528)

  • 61. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team.
    Aweeka FT; Kang M; Yu JY; Lizak P; Alston B; Chung RT;
    HIV Med; 2007 Jul; 8(5):288-94. PubMed ID: 17561874
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy).
    Casado A; Badia X; Consiglio E; Ferrer E; González A; Pedrol E; Gatell JM; Azuaje C; Llibre JM; Aranda M; Barrufet P; Martínez-Lacasa J; Podzamczer D;
    HIV Clin Trials; 2004; 5(3):132-9. PubMed ID: 15248137
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of zidovudine treatment in late pregnancy on HIV-1 in utero transmission.
    Taneepanichskul S; Sirinavin S; Phuapradit W; Chaturachinda K
    Aust N Z J Obstet Gynaecol; 1997 Aug; 37(3):329-31. PubMed ID: 9325519
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers.
    Barry M; Wild M; Veal G; Back D; Breckenridge A; Fox R; Beeching N; Nye F; Carey P; Timmins D
    AIDS; 1994 Aug; 8(8):F1-5. PubMed ID: 7986398
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
    Staszewski S; Miller V; Rehmet S; Stark T; De Crée J; De Brabander M; Peeters M; Andries K; Moeremans M; De Raeymaeker M; Pearce G; Van den Broeck R; Verbiest W; Stoffels P
    AIDS; 1996 May; 10(5):F1-7. PubMed ID: 8724034
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
    Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
    AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection.
    Phuapradit W; Sirinavin S; Taneepanichskul S; Chaovavanich A; Wiratchai A; Sunthornkachit R; Puchaiwatanon O
    Aust N Z J Obstet Gynaecol; 1998 Aug; 38(3):288-92. PubMed ID: 9761155
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Persistence of Macrocytosis after Discontinuation of Zidovudine in HIV-Infected Patients.
    Yu I; Greenberg RN; Crawford TN; Thornton AC; Myint T
    J Int Assoc Provid AIDS Care; 2017; 16(5):512-515. PubMed ID: 28393661
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
    HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection.
    Simonelli C; Zanussi S; Sandri S; Comar M; Lucenti A; Talamini R; Bortolin MT; Giacca M; De Paoli P; Tirelli U
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):20-7. PubMed ID: 9928725
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero.
    Olivero OA; Shearer GM; Chougnet CA; Kovacs AA; Landay AL; Baker R; Stek AM; Khoury MM; Proia LA; Kessler HA; Sha BE; Tarone RE; Poirier MC
    AIDS; 1999 May; 13(8):919-25. PubMed ID: 10371172
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children.
    Engchanil C; Kosalaraksa P; Lumbiganon P; Lulitanond V; Pongjunyakul P; Thuennadee R; Tungsawad S; Suwan-apichon O
    J Med Assoc Thai; 2006 Aug; 89(8):1229-36. PubMed ID: 17048434
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.
    Welles SL; Pitt J; Colgrove R; McIntosh K; Chung PH; Colson A; Lockman S; Fowler MG; Hanson C; Landesman S; Moye J; Rich KC; Zorrilla C; Japour AJ
    AIDS; 2000 Feb; 14(3):263-71. PubMed ID: 10716502
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.
    Kamkamidze G; Sullivan T; Charbonneau T
    J Clin Virol; 2001 Aug; 22(1):143-8. PubMed ID: 11418362
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients.
    Rubinstein A; Mizrachi Y; Bernstein L; Shliozberg J; Golodner M; Liu GQ; Ochs HD
    AIDS; 2000 Mar; 14(4):F55-62. PubMed ID: 10770533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.